NO20076126L - Mutasjoner i OAS1-gener - Google Patents

Mutasjoner i OAS1-gener

Info

Publication number
NO20076126L
NO20076126L NO20076126A NO20076126A NO20076126L NO 20076126 L NO20076126 L NO 20076126L NO 20076126 A NO20076126 A NO 20076126A NO 20076126 A NO20076126 A NO 20076126A NO 20076126 L NO20076126 L NO 20076126L
Authority
NO
Norway
Prior art keywords
mutations
oas1
genes
oas1 genes
amino acid
Prior art date
Application number
NO20076126A
Other languages
English (en)
Norwegian (no)
Inventor
Shawn P Iadonato
Charles L Magness
Christina A Scherer
P Campion Fellin
Tory Hagen
Amy Olson
Original Assignee
Kineta Two Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kineta Two Llc filed Critical Kineta Two Llc
Publication of NO20076126L publication Critical patent/NO20076126L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20076126A 2005-05-04 2007-11-27 Mutasjoner i OAS1-gener NO20076126L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67768005P 2005-05-04 2005-05-04
PCT/US2006/016983 WO2006119363A2 (en) 2005-05-04 2006-05-03 Mutations in oas1 genes

Publications (1)

Publication Number Publication Date
NO20076126L true NO20076126L (no) 2008-01-30

Family

ID=37113984

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076126A NO20076126L (no) 2005-05-04 2007-11-27 Mutasjoner i OAS1-gener

Country Status (19)

Country Link
US (4) US20060275802A1 (enExample)
EP (4) EP2860246A1 (enExample)
JP (1) JP5303728B2 (enExample)
KR (3) KR20140109510A (enExample)
CN (2) CN103642898A (enExample)
AU (1) AU2006242152B2 (enExample)
BR (1) BRPI0611454A2 (enExample)
CA (1) CA2607575A1 (enExample)
HK (1) HK1209454A1 (enExample)
IL (1) IL187079A (enExample)
MX (1) MX2007013765A (enExample)
NO (1) NO20076126L (enExample)
NZ (1) NZ563785A (enExample)
PH (1) PH12014500829A1 (enExample)
RU (2) RU2465328C2 (enExample)
SG (2) SG10201502945PA (enExample)
UA (1) UA95446C2 (enExample)
WO (1) WO2006119363A2 (enExample)
ZA (1) ZA200710521B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1689888A2 (en) * 2003-10-23 2006-08-16 Illumigen Biosciences Inc. Detection of mutations in a gene associated with resistance to viral infection, oas1
UA95446C2 (ru) 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Мутаци в генах oas1
AU2007321877B2 (en) * 2006-08-01 2011-11-03 Kineta Two, Llc Pharmaceutical manufacturing methods
WO2011097519A2 (en) 2010-02-05 2011-08-11 The Translational Genomics Research Institute Methods and kits used in classifying adrenocortical carcinoma
CN103536900B (zh) * 2012-07-16 2017-06-16 江苏豪森药业集团有限公司 含有促红细胞生成素模拟肽的药物组合物
WO2016164216A1 (en) * 2015-04-09 2016-10-13 Isp Investments Inc. Method of cosmetic treatment to protect the skin from pollution and improve skin regeneration
CN106483282B (zh) * 2016-09-29 2018-08-31 北京世纪沃德生物科技有限公司 一种抗原稳定剂及其制备方法与应用
US20210315980A1 (en) * 2018-08-21 2021-10-14 Georgia State University Research Foundation, Inc. Treatment of flavivirus infections in humans using mus musculus resistant 2'-5' oligoadenylate synthetase 1b
JP7677978B2 (ja) * 2019-12-30 2025-05-15 ナンジン、ジェンスクリプト、バイオテック、カンパニー、リミテッド 遺伝子変異ライブラリーを構築する方法
CN114409744B (zh) * 2022-03-29 2022-10-04 深圳吉诺因生物科技有限公司 Hpv抗原表位及其鉴定方法、应用
WO2023245177A2 (en) * 2022-06-17 2023-12-21 The University Of Chicago Targeted nanomedicine for treating lung disorders

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863873A (en) * 1980-01-14 1989-09-05 Esa, Inc. Method for biological testing and/or developing pharmaceuticals for treatment of disorders
JPS60222842A (ja) 1984-04-19 1985-11-07 Fuji Photo Film Co Ltd ハロゲン化銀写真乳剤およびその製造方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
WO1991006309A1 (en) 1989-11-03 1991-05-16 Vanderbilt University Method of in vivo delivery of functioning foreign genes
DE4039415A1 (de) * 1990-02-03 1991-08-08 Boehringer Mannheim Gmbh Verfahren zur herstellung rekombinanter proteine ohne n-terminalen methioninrest
NZ236819A (en) 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5266459A (en) * 1992-02-24 1993-11-30 The Scripps Research Institute Gaucher's disease: detection of a new mutation in intron 2 of the glucocerebrosidase gene
DE4208916A1 (de) 1992-03-20 1993-09-23 Akzo Nv Polyesterfaser und verfahren zu deren herstellung
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US5915378A (en) 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
WO1995022245A1 (en) 1994-02-18 1995-08-24 Cleveland Clinic Foundation Antiviral transgenic plants, vectors, cells and methods
US5861300A (en) 1993-03-08 1999-01-19 The Cleveland Clinic Foundation Antiviral transgenic plants, vectors, cells and methods
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
US5597709A (en) * 1994-01-27 1997-01-28 Human Genome Sciences, Inc. Human growth hormone splice variants hGHV-2(88) and hGHV-3(53)
JPH10501519A (ja) 1994-03-07 1998-02-10 インヘイル・セラピューティック・システムズ インシュリンを肺に送給できる方法および組成物
US5597696A (en) 1994-07-18 1997-01-28 Becton Dickinson And Company Covalent cyanine dye oligonucleotide conjugates
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5514758A (en) 1994-09-30 1996-05-07 The Goodyear Tire & Rubber Company Process for making latex for high performance masking tape
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5480640A (en) 1995-05-02 1996-01-02 Schering Corporation Alpha interferon for treating prostate cancer
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5840565A (en) * 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
US6001336A (en) 1996-12-31 1999-12-14 Inhale Therapeutic Systems Processes for spray drying aqueous suspensions of hydrophobic drugs and compositions thereof
US5765887A (en) 1997-01-07 1998-06-16 P Ii Inc Apparatus and method for searching pockets and crevices
US5993738A (en) 1997-05-13 1999-11-30 Universal Air Technology Electrostatic photocatalytic air disinfection
US5855564A (en) 1997-08-20 1999-01-05 Aradigm Corporation Aerosol extrusion mechanism
AU9131698A (en) 1997-09-08 1999-03-29 Princeton University Human genes regulated by human cytomegalovirus and interferon
FR2770300B1 (fr) 1997-10-27 1999-12-31 Vincent Patrice Chritin Dispositif pour la mesure de la vitesse d'un fluide et pour la mesure des flux de particules solides ou liquides dans les fluides ou le vide
WO1999050437A1 (en) * 1998-03-30 1999-10-07 Esa, Inc. Methodology for predicting and/or diagnosing disease
US5958773A (en) 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
US20010034023A1 (en) * 1999-04-26 2001-10-25 Stanton Vincent P. Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
US20030165921A1 (en) * 2000-02-03 2003-09-04 Tang Y. Tom Novel nucleic acids and polypeptides
WO2001066689A2 (en) 2000-03-07 2001-09-13 Hyseq, Inc. Novel nucleic acids and polypeptides
JP2004502406A (ja) * 2000-03-09 2004-01-29 カイロン　コーポレイション ヒト遺伝子およびヒト遺伝子発現産物
US20020110815A1 (en) 2000-04-14 2002-08-15 James Lillie Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
FR2823224B1 (fr) 2001-04-04 2003-10-31 Pasteur Institut Utilisation de genes oas impliques dans la sensibilite/resistance a l'infection par les flaviviridae pour le criblage de molecules antivirales
DE10122206A1 (de) 2001-05-08 2002-11-28 Switch Biotech Ag Verwendung von Polypeptiden oder diese kodierende NukleInsäuren einer 2'-5'- Oligoadenylate Synthetase und/oder RNAseL zur Diagnose, Prävention oder Behandlung von Hauterkrankungen oder Wundheilung sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
AU2002341207A1 (en) 2001-05-08 2002-11-18 Switch Biotech Ag Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing
US6818420B2 (en) * 2002-02-27 2004-11-16 Biosource International, Inc. Methods of using FET labeled oligonucleotides that include a 3′-5′ exonuclease resistant quencher domain and compositions for practicing the same
GB0208928D0 (en) 2002-04-19 2002-05-29 Imp College Innovations Ltd Methods
WO2003092618A2 (en) * 2002-04-30 2003-11-13 University Of South Florida Materials and methods for prevention and treatment of rna viral diseases
AU2003299505A1 (en) * 2002-05-17 2004-06-03 Baylor College Of Medicine Identification of oligoadenylate synthetase-like genes
WO2004000998A2 (en) 2002-06-19 2003-12-31 Georgia State University Research Foundation, Inc. Compositions and methods for viral resistance genes
EP1689888A2 (en) 2003-10-23 2006-08-16 Illumigen Biosciences Inc. Detection of mutations in a gene associated with resistance to viral infection, oas1
NZ580169A (en) 2003-10-23 2011-04-29 Illumigen Biosciences Inc Detection of mutations in a gene associated with resistance to viral infection, OAS1 (SEQ ID NO:48)
UA95446C2 (ru) 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Мутаци в генах oas1

Also Published As

Publication number Publication date
RU2007144986A (ru) 2009-06-10
US8951768B2 (en) 2015-02-10
MX2007013765A (es) 2008-01-29
PH12014500829A1 (en) 2016-01-18
US20090291074A1 (en) 2009-11-26
US20120070424A1 (en) 2012-03-22
ZA200710521B (en) 2008-11-26
KR101476844B1 (ko) 2015-01-02
EP2314675A3 (en) 2011-09-07
KR20140109510A (ko) 2014-09-15
CN101203604A (zh) 2008-06-18
JP2009504135A (ja) 2009-02-05
EP2295552A3 (en) 2011-07-06
HK1209454A1 (en) 2016-04-01
EP2314675B1 (en) 2015-04-08
JP5303728B2 (ja) 2013-10-02
EP2295552A2 (en) 2011-03-16
US20060275802A1 (en) 2006-12-07
US20130142773A1 (en) 2013-06-06
IL187079A0 (en) 2008-02-09
KR20080011423A (ko) 2008-02-04
AU2006242152B2 (en) 2011-11-03
CA2607575A1 (en) 2006-11-09
SG175656A1 (en) 2011-11-28
WO2006119363A2 (en) 2006-11-09
US8030046B2 (en) 2011-10-04
UA95446C2 (ru) 2011-08-10
RU2465328C2 (ru) 2012-10-27
AU2006242152A1 (en) 2006-11-09
IL187079A (en) 2015-06-30
EP2860246A1 (en) 2015-04-15
NZ563785A (en) 2011-02-25
CN103642898A (zh) 2014-03-19
WO2006119363A3 (en) 2007-05-31
BRPI0611454A2 (pt) 2010-09-08
US9163222B2 (en) 2015-10-20
RU2012132651A (ru) 2014-02-10
KR20130084323A (ko) 2013-07-24
EP2314675A2 (en) 2011-04-27
SG10201502945PA (en) 2015-05-28
EP1877550A2 (en) 2008-01-16

Similar Documents

Publication Publication Date Title
NO20076126L (no) Mutasjoner i OAS1-gener
EA201070430A1 (ru) Мутированные гены синтазы ацетогидроксикислот в brassica
DK2104739T3 (da) Modificerede messenger-RNA-stabiliseringssekvenser til ekspression af gener i bakterieceller
EP1954708A4 (en) Methods and compositions involving intrinsic genes
CY1112924T1 (el) Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης
WO2009111508A3 (en) Metalloproteinase 9 and metalloproteinase 2 binding proteins
WO2009111450A3 (en) Metalloproteinase 9 binding proteins
EP2064316A4 (en) LOCAL SPECIFIC INKORPORATION OF NON-NATURAL AMINO ACIDS IN SWIVELING CELLS
WO2011137320A3 (en) Small molecule inhibitors of usp1 deubiquitinating enzyme activity
MX346001B (es) Polipeptidos de eritropoyetina animal modificados y sus usos.
DK2730277T3 (da) Lægemiddelbærer og lægemiddelbærerkit til at inhibere fibrose
WO2011008956A3 (en) Mammalian genes involved in infection
CY1111121T1 (el) Ετεροαρυλο ενωσεις χρησιμες ως αναστολεις ενζυμων ενεργοποiησης ε1
UA109418C2 (uk) Конструйований білок з цинковими пальцями, направлений на гени рослин, залучені до біосинтезу жирних кислот
IN2012DN03825A (enExample)
SG156690A1 (en) Mammalian genes involved in infection
SG165353A1 (en) Improved human interferon molecules and their uses
WO2010134939A3 (en) Mammalian genes involved in infection
WO2010039778A3 (en) Mammalian genes involved in infection
DE602006008827D1 (de) Herbizidresistenz verleihende gene grg23 und grg51
EP2004824A4 (en) NUCLEOTIDE SEQUENCES ENCODING ENZYMES IN BIOSYNTHESIS OF DIHYDROARTEMISINIC ACID
EA201000273A1 (ru) Белок-предшественник тиопептида, кодирующий его ген и его применение
ATE549638T1 (de) 13c-mr-bildgebung oder spektroskopie von zelltod
AU313669S (en) Injector carry pack
GB201008720D0 (en) RxLR-leader peptides and protein translocation

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ,